États-Unis -
anglais -
NLM (National Library of Medicine)
risedronate sodium tablet delayed release
teva pharmaceuticals usa inc - risedronate sodium monohydrate (unii: f67l43ut5c) (risedronic acid - unii:km2z91756z) - risedronate sodium 35 mg
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
risedronate sodium actavis once weekly 35mg film-coated tablets
accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
risedronate sodium accord 5 mg film coated tablets
accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 5 milligram(s) - bisphosphonates; risedronic acid
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
risedronate sodium accord once a week 35 mg film-coated tablets
accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
risedronate sodium accord 75 mg film coated tablets
accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 75 milligram(s) - bisphosphonates; risedronic acid
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
optinate 75mg film-coated tablets
accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 75 milligram(s) - bisphosphonates; risedronic acid
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
optinate once a week 35mg film-coated tablets
accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
risedronate pinewood 30 mg film-coated tablets
pinewood laboratories ltd - risedronate sodium - film-coated tablet - 30 milligram(s) - bisphosphonates; risedronic acid
États-Unis -
anglais -
NLM (National Library of Medicine)
atelvia- risedronate sodium tablet, delayed release
allergan, inc. - risedronate sodium hemi-pentahydrate (unii: hu2yaq274o) (risedronic acid - unii:km2z91756z), risedronate sodium monohydrate (unii: f67l43ut5c) (risedronic acid - unii:km2z91756z) - risedronate sodium anhydrous 30.1 mg - atelvia is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of atelvia for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. atelvia is contraindicated in patients with the following conditions: • abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see warnings and precautions (5.2) ] • inability to stand or sit upri
Irlande -
anglais -
HPRA (Health Products Regulatory Authority)
risedronate sodium accord 30 mg film-coated tablets
accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 30 milligram(s) - bisphosphonates; risedronic acid